Abstract For a long time, intraductal tumors of the pancreas were neglected because they were misdiagnosed as mucinous cystadenocarcinoma, ordinary ductal adenocarcinoma, or chronic pancreatitis. Only in recent years have they been recognized as clinical and pathological entities. Most common are the intraductal papillary-mucinous neoplasms. Although they show an adenoma-carcinoma sequence, they have proved to have a more favorable prognosis than ductal adenocarcinoma, when resected in a preinvasive state. Recently, it has become clear that they constitute a heterogeneous group with at least four subtypes. Their stratification reveals that the various intraductal papillary-mucinous neoplasm subtypes have different biological properties with different prognostic implications.

Keywords Intraductal papillary mucinous neoplasm · Pancreas · Outcome

Historical notes and a rising incidence

The pancreatic tumors that are characterized by an intraductal origin and growth pattern include intraductal papillary-mucinous neoplasms [3, 24, 41], intraductal tubular carcinomas [22, 45], intraductal tubular adenomas of the pyloric type [6], and intraductal acinar cell carcinomas [15]. Most common are the intraductal papillary-mucinous neoplasms (IPMNs). They are mucin-producing epithelial tumors that usually show a papillary architecture and are associated with dilatation of the ducts. Before 1990, these tumors were thought to be rare. They first started to be recognized approximately 20 years ago [31, 36, 39], when the many different names given to the tumor in the 1980s were replaced by the term IPMN [41]. This name was also introduced in the classification of exocrine pancreatic tumors propagated by the World Health Organization (WHO) [24] and the fascicles of the Armed Forces Institute of Pathology [44]. Since then, IPMNs have been reported with increasing frequency (Table 1) and currently account for about 7% of clinically diagnosed pancreatic neoplasms and up to 16% of surgically resected pancreatic neoplasms and for almost 50% of pancreatic cysts found incidentally [8, 17]. When only the cystic tumors of the pancreas are considered, IPMNs take first place, with a frequency of 24% [26].

The new incidence data on IPMNs raise the question whether their increase in number is real or not. Of course, it is difficult to accept that IPMNs might have been overlooked in the past, not only clinically but also morphologically. There are good reasons, however, to believe that IPMNs did always exist and did not really increase in frequency. One reason is related to the rapid improvements in modern imaging techniques, which enable more precise recognition of cystic lesions, even if they are small and
asymptomatic. Another is connected with the decreasing risk of pancreatic surgery. The most important fact, however, may be that until 1999, the distinction between IPMNs and mucinous cystic neoplasms (MCNs) was unclear, so that many IPMNs were classified as MCNs [50] or regarded as ductal adenocarcinomas or chronic pancreatitis.

Adenoma-carcinoma sequence

In IPMNs, the normal ductal epithelium is replaced by mucin-producing columnar cells showing papillary proliferations and variable degrees of cellular atypia, even within an individual neoplasm. They are graded according to the most atypical area as IPMN with low grade dysplasia (adenoma), IPMN with moderate dysplasia (borderline), and IPMN with high grade dysplasia (carcinoma in situ). An invasive component may be found in 38–50% of the cases [7, 26, 40, 43]. Progression from adenoma to carcinoma is estimated to occur at about 5 years [43]. IPMNs therefore provide a model of neoplastic progression from a benign intraductal neoplasm through increasing grades of dysplasia to invasive carcinoma.

Prognosis after resection

Between 80 and 90% of IPMNs are surgically resectable. For these IPMNs, a 5-year survival rate of 77–100% was reported, provided the tumors did not have an invasive component (Table 2). By contrast, IPMNs with an invasive component had a 3- to 5-year survival rate of only 36–46% [12, 16, 43] (Table 2). Interestingly, the survival rate did not appear to be dependent on the grade of dysplasia in the IPMN if there was no invasive component [12, 16, 43, 47]. These data imply that the overall outcome of IPMNs therefore largely depends on the presence of an invasive component. If the tumor is already invasive, criteria for a poor outcome are lymph node involvement, vascular invasion, and bilirubin elevation [13]. A comparison of the prognosis of all patients with invasive IPMNs with that of patients with ductal adenocarcinoma reveals that patients with IPMNs survive longer than those with ductal adenocarcinomas [29, 40, 43].

Several studies have reported recurrences after resection of noninvasive IPMNs, some of which revealed only moderate dysplasia [12, 43, 47, 48]. The recurrences were either local or metastatic (Table 2). To explain the recurrences, particularly the local ones, it has to be assumed that either tumor tissue was overlooked at the pancreatic resection margin, or an invasive component remained undetected in the resected specimen, or there was multifocal disease. The last possibility has to be considered if the surgical margins were negative and the recurrence occurred in the pancreatic remnant. This has been observed only in a few cases [40]. When metastatic recurrences occur, it is most likely that they resulted from inadequate sampling that failed to detect an invasive component. Regarding the impact of a positive resection margin on IPMN recurrence, it is interesting to note that it has been reported that even IPMNs with positive margins did not recur during a median follow-up period varying from 19–40 months [13, 48]. The reason for this phenomenon might be that the growth of the remaining intraductal tumor tissue is so slow that clinical symptoms

### Table 1 Incidence data on intraductal papillary-mucinous neoplasms

| Author          | Period 1       | Number of incidence | Period 2       | Number of incidence |
|-----------------|----------------|---------------------|----------------|---------------------|
| Sohn et al. [43]| 1987–2001     | 58                  | 2001–2003      | 78                  |
| Wada et al. [47]| 1988–2000     | 63                  | 2001–2003      | 37                  |
| Our series      | 1981–2000     | 55                  | 2001–2007      | 50                  |

### Table 2 Five year survival rate and recurrence in 349a intraductal papillary-mucinous neoplasms

|                      | Noninvasive 77–100% | Invasive 36–46% |
|----------------------|---------------------|-----------------|
| No recurrence        | 93–98.7%            | 52–70%          |
| Recurrence           | 1.3–7%              | 30–48%          |
| Local                | up to 6%            | 8–48%           |
| Distant (metastases) | 1%                  | 12%             |
| Both                 | 0%                  | 10–48%          |

### Table 3 Histopathological data on 105 intraductal papillary-mucinous neoplasms collected during a period of 26 years

| IPMN          | Gastric (n=27) | Intestinal (n=57) | Pancreatobiliary (n=7) | Oncocytic (n=14) |
|---------------|----------------|-------------------|------------------------|------------------|
| Noninvasive   | n=20 (65%)     | n=35 (62%)        | n=3 (43%)              | n=10 (72%)       |
| Invasive      | n=7 (35%)      | n=22 (38%)        | n=4 (57%)              | n=4 (28%)        |

[a [12, 43, 47]
only appear after a follow-up period of 2 to 3 years. However, even if intraductal recurrences may take a long time to become clinically apparent, a positive margin in any IPMN case should lead to further tissue resection.

**Histological type and prognosis**

In 1991, it was reported that the invasive component of IPMNs corresponded either to an ordinary ductal adeno-
carcinoma or, more frequently, to that of a mucinous (colloid) carcinoma [49]. This observation suggested that IPMNs form a group of heterogeneous neoplasms. A further argument for the heterogeneity of IPMNs was the detection of IPMNs in branch ducts rather than in the main duct, where most of the IPMNs are found. Finally, it was recognized that IPMNs differ in their histological and cytological features and in their mucin profile [3, 4, 18, 28, 32, 33]. Currently, four subtypes of IPMN can be distinguished: an intestinal type, a pancreatobiliary type, an oncocytic type, and a gastric type [18].

The most common type of IPMN is the intestinal type (Table 3). It usually occurs in the main duct of the pancreatic head [9] and shows a villous growth pattern similar to that of villous adenoma in the colon. It also expresses MUC2 and CDX2 but not MUC1 (Fig. 1a,b). When this IPMN type becomes invasive, the invasive component resembles mucinous (colloid) carcinoma [5, 28], a tumor of which at least 80% is composed of pools of extracellular mucin containing single cells or strands of neoplastic glandular epithelium or even a small component of signet ring cells. Patients with colloid carcinoma have a 55% 5-year survival rate after resection [5]. These tumors therefore seem to be much less aggressive than ordinary ductal adenocarcinomas.

The pancreatobiliary type of IPMN is much rarer than the intestinal type IPMN (Table 3). It shows complex arborizing papillae and expresses MUC1 only (Fig. 1c,d). Its invasive component usually corresponds to a conventional ductal adenocarcinoma. The prognosis of this type of IPMN, if invasive, seems to be similar to that of ductal adenocarcinoma and therefore poorer than that of the intestinal type of IPMN [4].

---

866 Virchows Arch (2007) 451:863–869

---

Fig. 2 IPMN of the gastric type showing severe cellular atypia and MUC5 positivity

---

Fig. 3 PanIN-1 lesion associated with lobular fibrosis

---

Fig. 4 Small multicystic duct-associated lesion in the periphery of pancreatic tissue suggestive of an IPMN of the gastric type but difficult to distinguish from a large PanIN-1 lesion
The oncocytic type of IPMN (also called intraductal oncocytic papillary neoplasm [2]) shows the same complex papillae as the pancreatic biliary type, but the lining cells reveal strongly eosinophilic cytoplasm. In addition, there are often numerous goblet cells. The tumor cells express MUC1 and MUC2 inconsistently (Fig. 1e,f). With fewer than 20 cases reported in the literature to date [2, 20, 34, 35, 37, 38, 42], the clinical and pathological behavior of this type is still unclear. Most of the cases (94%) were diagnosed as carcinoma, some of them with an invasive component or even distant metastases [37]. As the follow-up in this patient group is very short, no relevant data are available yet on survival and outcome.

The gastric type of IPMN exhibits papillary projections lined by epithelial cells resembling gastric foveolar cells and shows pyloric gland-like structures at the base of the papillae. These cells express MUC5 (Fig. 1g,h), while MUC1, MUC2, or CDX2 positivity is only occasionally observed. The gastric type of IPMN corresponds to the branch duct type, which occurs in the periphery of the pancreatic parenchyma, most often in the uncinate process, where it usually presents as a multicystic lesion with cysts no larger than 3 cm [9]. The gastric type seems to be less aggressive, i.e., less invasive, than the other IPMN subtypes [10, 25, 33, 46] but may show severe cellular atypia in a few cases (up to 25%) [46] (Table 3, Fig. 2) The size of the lesion was unrelated to the grade of cellular atypia [46].

Interestingly, pancreatic intraepithelial neoplasia (PanIN)-like complexes are frequently observed next to gastric type IPMNs. This raises the question whether IPMNs of the gastric type are a focal accentuation of a diffuse disease rather than a localized lesion. They might therefore also be related to the small peripheral cystic changes described by Kimura et al. [21] in non-neoplastic pancreata or the patchy lobular fibrosis associated with PanIN-1B lesions described by Detlefsen et al. [14] (Fig. 3). If this were the case, IPMNs of the gastric type would actually be large PanIN-1 lesions. An argument for this assumption is that both IPMNs of the gastric type and PanIN-1 lesions stain for MUC5 in the absence of MUC1 and MUC2 positivity. This assumption would also explain why it is difficult to distinguish PanIN lesions from some IPMNs [27] (Fig. 4), despite a consensus definition of both lesions [19].

Although the malignant potential of IPMNs of the gastric type seems to be rather low, it has to be pointed out that the fibrocystic changes that have been described in pancreata removed from patients with a strong family history of pancreatic cancer [11, 30] are similar, if not identical, to IPMNs of the gastric type and their associated PanIN lesions. This implies that IPMNs of the gastric type/PanIN-1 lesions are not innocuous lesions but have a malignant potential.

Summary and perspectives

The significance of IPMNs among the pancreatic tumors has increased greatly in recent years because of their improved recognition, both clinically and histopathologically and their much better prognosis than ordinary ductal adenocarcinomas. Moreover, they appear to fall into four subtypes that have special biological properties with prognostic implications. Of particular interest in relation to the development of ductal adenocarcinomas is the fact that the so-called gastric type IPMNs seems to occur in pancreata from patients with a strong family history of pancreatic cancer. Furthermore, it is of interest that the pancreatic IPMNs have their counterparts in IPMNs of the biliary duct system, where the same subtypes may occur [1, 23, 51, 52]. The treatment of choice is resection, but future trials may reveal that the extent of resection could depend on the IPMN subtype.

References

1. Abraham SC, Lee JH, Hruban RH, Argani P, Furth EE, Wu TT (2003) Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract. Hum Pathol 34:902–910
2. Adsay NV, Adair CF, Heffess CS, Klimstra DS (1996) Intraductal oncocytic papillary neoplasms of the pancreas. Am J Surg Pathol 20:980–994
3. Adsay NV, Conlon KC, Zee SY, Brennan MF, Klimstra DS (2002) Intraductal papillary-mucinous neoplasms of the pancreas. An analysis of in situ and invasive carcinomas in 28 patients. Cancer 94:62–77
4. Adsay NV, Merati K, Basturk O, Iacobuzio-Donahue C, Levi E, Cheng JD, Sarkar FH, Hruban RH, Klimstra DS (2004) Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms. Delineation of an “intestinal” pathway of carcinogenesis in the pancreas. Am J Surg Pathol 28:839–848
5. Adsay NV, Pierson C, Sarkar F, Abrams J, Weaver D, Conlon KC, Brennan MF, Klimstra DS (2001) Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol 25:26–42
6. Albores-Saavedra J, Sheahan K, O’Riain C, Shukla D (2004) Intraductal tubular adenoma, pyloric type, of the pancreas. Additional observations on a new type of pancreatic neoplasm. Am J Surg Pathol 28:233–238
7. Azar C, Van de Stadt J, Rickaert F, Devière J, Delhaye M, Baize M, Klöppel G, Gelin M, Cremer M (1996) Intraductal papillary mucinous tumours of the pancreas. Clinical and therapeutic issues in 32 patients. Gut 39:457–464
8. Balzano G, Zerbi A, Di Carlo V (2005) Intraductal papillary mucinous tumours of the pancreas: incidence, clinical findings and natural history. JOP 6(1 Suppl):108–111
9. Ban S, Naitoh Y, Mino-Kenudson M, Sakurai T, Kuroda M, Koyama I, Lauwers GY, Shimizu M (2006) Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: histopathologic difference between 2 major types. Am J Surg Pathol 30:1561–1569
10. Ban S, Naitoh Y, Ogawa F, Shimizu Y, Shimizu M, Yasumoto A, Koyama I (2006) Intraductal papillary mucinous neoplasm...
(IPMN) of the gastric-type with focal nodular growth of the arborizing papillae: a case of high-grade transformation of the gastric-type IPMN. Virchows Arch 449:112–116.

11. Brune K, Abe T, Canto M, O’Malley L, Klein AP, Maitra A, Adsay NV, Fishman EK, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH (2006) Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 30:1067–1076.

12. Chari ST, Yadav D, Smyrk TC, DiMagno EP, Miller LJ, Raimondo M, Clain JE, Norton IA, Pearson RK, Petersen BT, Wiersema MJ, Farnell MB, Sarr MG (2002) Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 123:1500–1502.

13. D’Angelica M, Brennan MF, Suriawinata AA, Klöppel D, Conlon KC (2004) Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg 239:400–408.

14. Detlefsen S, Sipos B, Feyerabend B, Klöppel G (2005) Pancreatic fibrosis associated with age and ductal papillary hyperplasia. Virchows Arch 447:800–805.

15. Fabre A, Sauvanet A, Fléjou JF, Belghiti J, Palazzo L, Ruzniewski P, Degott C, Teras S (2001) Intraductal acinar cell carcinoma of the pancreas. Virchows Arch 438:312–315.

16. Falconi M, Salvia R, Bassi C, Zamboni G, Pederzoli P (2001) Clinicopathologic features and treatment of intraductal papillary mucinous tumour of the pancreas. Br J Surg 88:376–381.

17. Fernandez-del Castillo C, Targorona I, Thayer SP, Rattner DW, Brugge WR, Warshaw AL (2003) Incidental pancreatic cysts: a clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 138:427–433 (discussion 433–434).

18. Furukawa T, Klöppel G, Volkan AN, Albores-Saavedra J, Fukushima N, Horii A, Hruban RH, Kato Y, Klöppel D, Longnecker DS, Lüttges J, Offerhaus GJA, Shimizu M, Yonezawa S (2005) Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 447:794–799.

19. Hruban RH, Takaori K, Klöppel D, Adsay NV, Albores-Saavedra J, Biankin AV, Biankin SA, Compton C, Fukushima N, Furukawa T, Goggins M, Kato Y, Klöppel G, Longnecker DS, Lüttges J, Maitra A, Offerhaus GJA, Shimizu M, Yonezawa S (2004) An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28:977–987.

20. Jyotheeswaran S, Zotalis G, Penneta P, Levea CM, Schoeniger LO, Shah AN (1998) A newly recognized entity: intraductal “oncocytic” papillary neoplasms of the pancreas. Am J Gastroenterol 93:2539–2543.

21. Kimura W, Naiag H, Kuroda A, Muto T, Esaki Y (1995) Analysis of small cystic lesions of the pancreas. Int J Pancreatol 18:197–206.

22. Klöppel D, Adsay NV, Dhall D, Shimizu M, Cymes K, Basturk O, Klöppel G (2007) Intraductal tubular carcinoma of the pancreas: clinicopathologic and immunohistochemical analysis of 18 cases (Abstract). Lab Invest 87(Suppl 1):285A.

23. Klöppel G, Kosmahl M (2006) Is the intraductal papillary mucinous neoplasm of the biliary tract a counterpart of pancreatic papillary mucinous neoplasm? J Hepatol 44:249–250.

24. Klöppel G, Solcia E, Longnecker DS, Capella C, Sobin LH (1996) Histological typing of tumours of the exocrine pancreas, 2nd edn. WHO International histological classification of tumours. Springer, Berlin.

25. Kobari M, Egawa S, Shibuya K, Shimamuru H, Sunamura M, Takeda K, Matsuno S, Furukawa T (1999) Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg 134:1131–1136.

26. Kosmahl M, Pauser U, Peters K, Sipos B, Lüttges J, Kremer B, Klöppel G (2004) Cystic neoplasms of the pancreas and tumor-like lesions with cystic features: a review of 418 cases and a classification proposal. Virchows Arch 445:168–178.

27. Longnecker DS, Adsay NV, Fernandez-del Castillo C, Hruban RH, Kasugai T, Klöppel D, Lüttges J, Memoli VA, Tosteson TD, Yanagisawa A, Wilentz R, Zamboni G (2005) Histopathologic diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. Pancreas 31:344–349.

28. Lüttges J, Zamboni G, Longnecker D, Klöppel G (2001) The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncytic carcinoma and ductal adenocarcinoma. Am J Surg Pathol 25:942–948.

29. Maire F, Hammel P, Teras S, Paye F, Scoazec JY, Cellier C, Barhet M, O’Toole D, Rufat P, Partensky C, Cuillerier E, Levy P, Belghiti J, Ruzniewski P (2002) Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 51:717–722.

30. Meckler KA, Brentnall TA, Haggitt RC, Crispin D, Byrd DR, Kimme MB, Bronner MP (2001) Familial fibrocystic pancreatic atrophy with endocrine cell hyperplasia and pancreatic carcinoma. Am J Surg Pathol 25:1047–1053.

31. Morohoshi T, Kanda M, Asanuma K, Klöppel G (1989) Intraductal papillary neoplasms of the pancreas. A clinicopathologic study of six patients. Cancer 64:1329–1335.

32. Nakamura A, Horinouchi M, Saitou M, Higashi M, Nomoto M, Goto M, Yonezawa S (2007) Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg 14:243–254.

33. Nakamura A, Horinouchi M, Goto M, Nanaka K, Sakada K, Takao S, Imai K, Kim YS, Sato E, Yonezawa S (2002) New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol 197:201–210.

34. Nobukawa T, Suda K, Suyama M, Aiyama Y, Beppu T, Futagawa S (1999) Intraductal oncocytic papillary carcinoma with invasion arising from the accessory pancreatic duct. Gastrointest Endosc 50:864–866.

35. Noji T, Kondo S, Hirano S, Ambo Y, Tanaka E, Katoh C, Tsukamoto E, Tamaki N, Katoh H (2002) Intraductal oncocytic papillary neoplasm of the pancreas shows strong positivity on FDG-PET. Int J Gastrointest Cancer 32:43–46.

36. Ohashi K, Murakami F, Takedo K et al (1982) Four cases of “mucin-producing” cancer of the pancreas on specific findings of the papilla of Vater (Japanese). Proc Dig Endosc 20:348.

37. Oku T, Maeda M, Wada Y, Waga E, Ono K, Nagamachi Y, Fujii S, Fujita M, Misu K, Semmaru N, Suzuki Y, Nagashima K, Niitsu Y (2007) Intraductal oncocytic papillary neoplasm having clinical characteristics of mucinous cystic neoplasm and a benign histology. JOP 8:206–213.

38. Patel SA, Adams R, Goldstein M, Moskaluk CA (2002) Genetic analysis of invasive carcinoma arising in intraductal oncocytic papillary neoplasm of the pancreas. Am J Surg Pathol 26:1071–1077.

39. Rickaert F, Cremer M, Deviere J, Tavares L, Lambilliotte JP, Schröder S, Wurfs D, Klöppel G (1991) Intraductal mucin-hypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients. Gastroenterology 101:519–528.

40. Salvia R, Fernandez-del Castillo C, Bassi C, Thayer SP, Falconi M, Mantovani W, Pederzoli P, Warshaw AL (2004) Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 239:678–685.
41. Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, Pellegata NS, Ranzani GN, Rickaert F, Klöppel G (1994) Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53, and c-erbB-2 abnormalities in 26 patients. Virchows Arch 425:357–367

42. Shima Y, Yagi T, Inagaki M, Sadamori H, Tanaka N, Horimi T, Hamazaki S (2005) Intraductal oncocytic papillary neoplasm of the pancreas with celiac artery compression syndrome and a jejunal artery aneurysm: report of a case. Surg Today 35:86–90

43. Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, Lillemoe KD (2004) Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 239:788–797

44. Solcia E, Capella C, Klöppel G (1997) Tumors of the pancreas. AFIP Atlas of Tumor Pathology, third series, fascicle 20. Armed Forces Institute of Pathology, Washington, DC

45. Tajiri T, Tate G, Inagaki T, Kunimura T, Inoue K, Mitsuya T, Yoshida M, Morohoshi T (2005) Intraductal tubular neoplasms of the pancreas. Histogenesis and differentiation. Pancreas 30:115–121

46. Terris B, Ponsot T, Paye F, Hammel P, Sauvanet A, Molas G, Bernades P, Belghiti J, Ruszniewski P, Fléjou JF (2000) Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 24:1372–1377

47. Wada K, Kozarek RA, Traverso LW (2005) Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg 189:632–637

48. White R, D’Angelica M, Katabi N, Tang L, Klimstra D, Fong Y, Brennan M, Allen P (2007) Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg 204:987–995

49. Yamada M, Kozuka S, Yamao K, Nakazawa S, Naitoh Y, Tsukamoto Y (1991) Mucin-producing tumor of the pancreas. Cancer 68:159–168

50. Zamboni G, Scarpa A, Bogina G, Iacono C, Bassi C, Talamini G, Sessa F, Capella C, Solcia E, Rickaert F, Mariuzzi GM, Klöppel G (1999) Mucinous cystic tumors of the pancreas. Clinicopathological features, prognosis and relationship to other mucinous cystic tumors. Am J Surg Pathol 23:410–422

51. Zen Y, Fujii T, Itatsu K, Nakamura K, Konishi F, Masuda S, Mitsui T, Asada Y, Miura S, Miyayama S, Uehara T, Katsuyama T, Ohta T, Minato H, Nakanuma Y (2006) Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct. Mod Pathol 19:1243–1254

52. Zen Y, Fujii T, Itatsu K, Nakamura K, Minato H, Kasashima S, Kurumaya H, Katayanagi K, Kawashima A, Masuda S, Niwa H, Mitsui T, Asada Y, Miura S, Ohta T, Nakanuma Y (2006) Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44:1333–1343